Boothbay Fund Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Boothbay Fund Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-14,446	Closed	-$72.1K	–	2401
2025 Q3	$72.1K	Buy	+14,446	New	+$66.9K	﹤0.01%	1760
2024 Q4	–	Sell	-17,344	Closed	-$81.3K	–	1934
2024 Q3	$81.3K	Buy	+17,344	New	+$93K	﹤0.01%	1473
2020 Q3	–	Sell	-298,605	Closed	-$3.42M	–	1234
2020 Q2	$3.42M	Buy	298,605 +20,505	+7%	+$232K	0.23%	100
2020 Q1	$2.88M	Buy	278,100 +130,100	+88%	+$1.61M	0.24%	102
2019 Q4	$2.43M	Sell	148,000 -1,139	-0.8%	-$17.2K	0.21%	117
2019 Q3	$1.98M	Buy	149,139 +28,141	+23%	+$392K	0.18%	146
2019 Q2	$1.71M	Buy	120,998 +85,064	+237%	+$1.35M	0.16%	169
2019 Q1	$661K	Buy	35,934 +26,171	+268%	+$596K	0.06%	310
2018 Q4	$255K	Buy	+9,763	New	+$230K	0.04%	428
2018 Q2	–	Sell	-19,346	Closed	-$326K	–	907
2018 Q1	$326K	Buy	+19,346	New	+$324K	0.04%	448

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KAM

Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return

Boothbay Fund Management's VNDA Position: Q4 2025 in Review

Boothbay Fund Management sold out of Vanda Pharmaceuticals (VNDA) in Q4 2025, closing a stake of 14,446 shares — an estimated $72.1K sold.

Boothbay Fund Management first reported a position in VNDA in Q1 2018 and held it in 10 quarters. The position peaked at $3.42M in Q2 2020. 153 funds tracked by Wall St. Rank hold VNDA as of Q4 2025.

Boothbay Fund Management reported no remaining Vanda Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Boothbay Fund Management sold 14,446 Vanda Pharmaceuticals shares in Q4 2025, an estimated $72.1K.
Boothbay Fund Management first reported a position in Vanda Pharmaceuticals in Q1 2018 and held it in 10 quarters.
Boothbay Fund Management's Vanda Pharmaceuticals position peaked at $3.42M in Q2 2020.
153 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.